Is Mazor Robotics Really on Track for Its Best Quarter Ever?

Equities analysts expect Mazor Robotics Ltd. (NASDAQ:MZOR) to report earnings of ($0.25) per share for the current quarter, according to Zacks. Four analysts have made estimates for ImmunoGen's earnings; with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.38). The company is planned to issue its next earnings results on Thursday, August 3rd. On average, equities research analysts expect that Mazor Robotics will post ($0.75) EPS for the current year.

Mazor Robotics (NASDAQ:MZOR) last released its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.22) EPS for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.02.

Thomson Reuters consensus estimates are calling for only $12.36 million in this quarter, so Mazor might see a pretty solid beat. Mazor Robotics had a negative return on equity of 30.90% and a negative net margin of 45.08%. During the same period in the previous year, the company earned ($0.10) earnings per share. Zacks' earnings per share averages are an average based on a survey of sell-side research firms that follow ImmunoGen. They noted that the move was a valuation call. Finally, JMP Securities downgraded shares of Mazor Robotics from an "outperform" rating to a "market perform" rating in a research note on Friday, May 12th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Mazor Robotics has a consensus rating of "Hold" and an average target price of $33.50.

Tony Blair 'not straight with the nation' on Iraq War decisions
The father of a Sheffield soldier killed in the Iraq War has defended former prime minister Tony Blair in the wake of fresh criticism.

Shares of Mazor Robotics (NASDAQ MZOR) traded up 0.78% during midday trading on Wednesday, reaching $33.75. Wells Fargo & Company MN now owns 40,958 shares of the medical instruments supplier's stock worth $1,220,000 after buying an additional 12,959 shares during the period. The stock has a 50 day moving average price of $37.52 and a 200 day moving average price of $28.88.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another site, it was stolen and republished in violation of United States and global copyright law.

WARNING: "Mazor Robotics Ltd. (MZOR) Upgraded at ValuEngine" was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. Hedge funds and other institutional investors own 26.89% of the company's stock. Finally, Messner & Smith Theme Value Investment Management Ltd. CA acquired a new stake in shares of Mazor Robotics during the first quarter worth approximately $872,000. Credit Suisse AG increased its position in shares of Mazor Robotics by 66.5% in the first quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier's stock valued at $208,000 after buying an additional 5,579 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Mazor Robotics during the first quarter valued at about $709,000. Morgan Stanley now owns 8,520 shares of the medical instruments supplier's stock worth $254,000 after buying an additional 2,215 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its stake in shares of Mazor Robotics by 26.7% in the first quarter. Accern also gave news stories about the medical instruments supplier an impact score of 25 out of 100, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the next few days.